CBI is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and which has now been detected in 60 locations internationally, including in the United States. The virus has been named “SARS-CoV-2” and the disease it causes has been named “coronavirus disease 2019” (abbreviated “COVID-19”).
We are already responding to researchers and our sponsor’s requests to plan and design preclinical pharmacology, toxicology and safety studies to assess new and novel treatment and vaccines for COVID-19. We are ready to initiate these studies immediately and to help our clients advance their products with all possible speed. This is an emerging, rapidly evolving situation and Comparative Biosciences, Inc. will provide updated information as it becomes available, in addition to updated guidance.
What May Happen?
More cases of COVID-19 are likely to be identified in the coming days, including more cases in the United States. It’s also likely that person-to-person spread will continue to occur, including in communities in the United States. It’s likely that at some point, widespread transmission of COVID-19 in the United States will occur.
Widespread transmission of COVID-19 would translate into large numbers of people needing medical care at the same time. Schools, childcare centers, workplaces, and other places for mass gatherings may experience more absenteeism. Public health and healthcare systems may become overloaded, with elevated rates of hospitalizations and deaths. Other critical infrastructure, such as law enforcement, emergency medical services, and transportation industry may also be affected. Health care providers and hospitals may be overwhelmed. At this time, there is no vaccine to protect against COVID-19 and no medications approved to treat it. Nonpharmaceutical interventions would be the most important response strategy.
What are coronaviruses?
Coronavirus refers to a family of viruses that have a crown-like (“corona”) appearance that cause disease in animals and humans. In humans, coronaviruses cause respiratory tract infections that are typically mild, like the common cold. Some coronaviruses seem more severe, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).
How is it spread? (what we understand so far)
- Mainly person-to-person through respiratory droplets.
- May also spread through contact with contaminated surfaces (and then you touch your eyes, mouth, face).
- Symptoms may appear 2-14 days after exposure.
The best studied model for coronavirus replication and pathogenesis has been the group 2 murine coronavirus, mouse hepatitis virus, and much of what is known of the stages of the coronavirus life cycle has been determined in animals and in culture using this virus. Thus this discussion will focus on MHV with comparisons to SCoV and other coronaviruses. This is appropriate because bioinformatics analyses suggest that SCoV, while a distinct virus, has significant similarities in organization, putative protein functions, and replication to the group II coronaviruses, particularly within the replicase gene (Snijder et al., 2003). Excellent, detailed reviews of MHV and coronavirus replication are available elsewhere.
Contact Comparative Biosciences, Inc. to discuss a scientific study program for Coronavirus Disease Studies and Services.
Comparative Biosciences, Inc. · Phone: 408.738.9260
– CUSTOM CORONAVIRUS DISEASE STUDIES UPON REQUEST –